Predicting circulating CA125 levels among healthy premenopausal women

File Description SizeFormat 
Manuscript_revisedv2.docxFile embargoed until 04 April 2020156.83 kBMicrosoft Word    Request a copy
Supplementary Data_revised.docxFile embargoed until 04 April 202042.65 kBMicrosoft Word    Request a copy
Title: Predicting circulating CA125 levels among healthy premenopausal women
Authors: Sasamoto, N
Babic, A
Rosner, BA
Fortner, RT
Vitonis, AF
Yamamoto, H
Fichorova, RN
Tjønneland, A
Hansen, L
Overvad, K
Kvaskoff, M
Fournier, A
Mancini, FR
Boeing, H
Trichopoulou, A
Peppa, E
Karakatsani, A
Palli, D
Pala, V
Mattiello, A
Tumino, R
Grasso, C
Onland-Moret, NC
Weiderpass, E
Quirós, JR
Lujan-Barroso, L
Rodríguez-Barranco, M
Colorado-Yohar, S
Barricarte, A
Dorronsoro, M
Idahl, A
Lundin, E
Sartor, H
Khaw, K-T
Key, TJ
Muller, D
Riboli, E
Gunter, M
Dossus, L
Kaaks, R
Cramer, DW
Tworoger, SS
Terry, KL
Item Type: Journal Article
Abstract: Background: CA125 is the most promising ovarian cancer screening biomarker to date. Multiple studies reported CA125 levels vary by personal characteristics, which could inform personalized CA125 thresholds. However, this has not been well described in premenopausal women. Methods: We evaluated predictors of CA125 levels among 815 premenopausal women from the New England Case Control Study (NEC). We developed linear and dichotomous (≥ 35 U/ mL) CA125 prediction models and externally validated an abridged model restricting to available predictors among 473 premenopausal women in the European Prospective Investigation into Cancer and Nutrition Study (EPIC). Results: The final linear CA125 prediction model included age, race, tubal ligation, endometriosis, menstrual phase at blood draw, and fibroids, which explained 7% of the total variance of CA125. The correlation between observed and predicted CA125 levels based on the abridged model (including age, race, and menstrual phase at blood draw) had similar correlation coefficients in NEC(r=0.22) and in EPIC(r=0.22). The dichotomous CA125 prediction model included age, tubal ligation, endometriosis, prior personal cancer diagnosis, family history of ovarian cancer, number of miscarriages, menstrual phase at blood draw and smoking status with AUC of 0.83. The abridged dichotomous model (including age, number of miscarriages, menstrual phase at blood draw, and smoking status) showed similar AUCs in NEC(0.73) and in EPIC(0.78). Conclusions: We identified a combination of factors associated with CA125 levels in premenopausal women. Impact: Our model could be valuable in identifying healthy women likely to have elevated CA125 and consequently improve its specificity for ovarian cancer screening.
Issue Date: 1-Jun-2019
Date of Acceptance: 21-Feb-2019
URI: http://hdl.handle.net/10044/1/67999
DOI: https://doi.org/10.1158/1055-9965.EPI-18-1120
ISSN: 1055-9965
Publisher: American Association for Cancer Research
Start Page: 1076
End Page: 1085
Journal / Book Title: Cancer Epidemiology, Biomarkers and Prevention
Volume: 28
Issue: 6
Copyright Statement: ©2019 American Association for Cancer Research.
Sponsor/Funder: Imperial College Trust
Funder's Grant Number: P47328
Keywords: Science & Technology
Life Sciences & Biomedicine
Oncology
Public, Environmental & Occupational Health
OVARIAN-CANCER RISK
CA-125 LEVELS
MODELS
REPRODUCIBILITY
MORTALITY
VALIDITY
PROSTATE
LUNG
Epidemiology
11 Medical and Health Sciences
Publication Status: Published
Embargo Date: 2020-04-04
Online Publication Date: 2019-04-04
Appears in Collections:Faculty of Medicine
Epidemiology, Public Health and Primary Care



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons